DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response
We demonstrate that DLBCL cells surviving CD19 CAR T-cell treatment develop a resistance phenotype with a "resistance signature" predictive of clinical CAR T-cell response, mediating cross-resistance between CAR T cells targeting different antigens. Our findings suggest that up-front dual-antigen targeting and combination therapies could improve clinical outcomes.
Authors
- Jeanne Whalen (ORCID: https://orcid.org/0009-0002-2442-7511)
- Youngchul Song (ORCID: https://orcid.org/0000-0001-5681-6429)
- Jennifer L. Brogdon (ORCID: https://orcid.org/0000-0002-2084-832X)
- Sarah M. Choi (ORCID: https://orcid.org/0000-0002-7028-7313)
- Louise M. Treanor (ORCID: https://orcid.org/0000-0001-5685-6711)
- Joseph A. Fraietta (ORCID: https://orcid.org/0000-0001-7900-8993)
- Rick Newcombe (ORCID: https://orcid.org/0009-0002-5446-9034)
- Kalyn Schriefer (ORCID: https://orcid.org/0009-0002-4695-9906)
- Stephen J. Schuster (ORCID: https://orcid.org/0000-0002-3376-8978)
- Matthew J. Niederst (ORCID: https://orcid.org/0000-0002-7807-9586)
- Marco Ruella (ORCID: https://orcid.org/0000-0003-4301-5811)
- Elena J. Orlando (ORCID: https://orcid.org/0009-0004-6448-8874)
- Fabiana Lüönd (ORCID: https://orcid.org/0000-0002-7444-1648)
Institutions
- Boston Biomedical Research Institute (US)
- Hospital of the University of Pennsylvania (US)
- Boston Biomedical (United States) (US)
- Parker Institute for Cancer Immunotherapy (US)
- Novartis (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Blood Cancer Discovery
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1158/2643-3230.bcd-24-0176
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00